1. Home
  2. STOK vs NPKI Comparison

STOK vs NPKI Comparison

Compare STOK & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • NPKI
  • Stock Information
  • Founded
  • STOK 2014
  • NPKI 1932
  • Country
  • STOK United States
  • NPKI United States
  • Employees
  • STOK N/A
  • NPKI 1550
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • NPKI Metal Fabrications
  • Sector
  • STOK Health Care
  • NPKI Industrials
  • Exchange
  • STOK Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • STOK 721.4M
  • NPKI 665.2M
  • IPO Year
  • STOK 2019
  • NPKI N/A
  • Fundamental
  • Price
  • STOK $9.36
  • NPKI $7.70
  • Analyst Decision
  • STOK Strong Buy
  • NPKI
  • Analyst Count
  • STOK 8
  • NPKI 0
  • Target Price
  • STOK $21.83
  • NPKI N/A
  • AVG Volume (30 Days)
  • STOK 933.4K
  • NPKI 484.1K
  • Earning Date
  • STOK 11-05-2024
  • NPKI 02-19-2025
  • Dividend Yield
  • STOK N/A
  • NPKI N/A
  • EPS Growth
  • STOK N/A
  • NPKI N/A
  • EPS
  • STOK N/A
  • NPKI N/A
  • Revenue
  • STOK $16,742,999.00
  • NPKI $748,372,000.00
  • Revenue This Year
  • STOK $105.42
  • NPKI N/A
  • Revenue Next Year
  • STOK N/A
  • NPKI N/A
  • P/E Ratio
  • STOK N/A
  • NPKI N/A
  • Revenue Growth
  • STOK 81.08
  • NPKI 93.70
  • 52 Week Low
  • STOK $4.09
  • NPKI $5.61
  • 52 Week High
  • STOK $17.58
  • NPKI $8.65
  • Technical
  • Relative Strength Index (RSI)
  • STOK 36.22
  • NPKI N/A
  • Support Level
  • STOK $8.42
  • NPKI N/A
  • Resistance Level
  • STOK $9.77
  • NPKI N/A
  • Average True Range (ATR)
  • STOK 0.66
  • NPKI 0.00
  • MACD
  • STOK -0.09
  • NPKI 0.00
  • Stochastic Oscillator
  • STOK 28.40
  • NPKI 0.00

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

About NPKI NPK International Inc. Common Stock

NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.

Share on Social Networks: